The University of Missouri has partnered with AI Proteins, a biotechnology company focused on designing therapeutic miniproteins, to advance targeted radioligand therapy for patients with cancer. The collaboration focuses on developing miniproteins labeled with radionuclides to target multiple tumor-associated antigens simultaneously. 

“AI Proteins recognizes Dr. Carolyn Anderson and her team as leaders in molecular imaging and theranostics research,” said Dr. Chris Bahl, founder, President, and CEO of AI Proteins “By working together, we have the opportunity to take a major step forward for patients who are battling cancer.” 

The research is expected to result in a platform that can be applied to various cancers.